The Journal of dermatological treatment · 2026
A cross-sectional analysis of topical steroid phobia and observable side effects in Thai psoriasis patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Piemmongkolchai Pimmada, Khamkaen Chawengsak, Woramongkol Thanakorn, Kulthanan Kanokvalai, Wongpraparut Chanisada, Silpa-Archa Narumol, Chaiyabutr Chayada, Leeyaphan Charussri
Аннотация
BACKGROUND: Steroid phobia impairs adherence to topical corticosteroids (TCS) and undermines psoriasis management, yet remains understudied in adult Thai patients.
OBJECTIVES: To quantify TCS phobia using the TOPICOP scale in Thai adults with psoriasis and identify associated factors.
METHODS: A cross-sectional survey at Siriraj Hospital enrolled 150 adults with psoriasis and TCS experience, who completed the validated Thai TOPICOP scale.
RESULTS: Of 150 participants, 81 (54.0%) were female, median age 52 years (IQR 35.0-62.3). Mean TOPICOP score was 17.1 ± 5.3/36 (47.5% ± 14.7%). Forty percent reported explicit fear of TCS. Dermatologist-confirmed side effects, most commonly skin atrophy, were present in 50.0% and associated with higher TOPICOP scores (18.1 ± 4.3 vs. 16.0 ± 6.0; p = 0.016). Facial involvement was also associated with higher scores (18.1 ± 5.0 vs. 16.3 ± 5.4; p = 0.032). TOPICOP scores correlated positively with DLQI (r = 0.175; p = 0.030) and educational level (r = 0.240; p = 0.003).
CONCLUSIONS: TCS phobia is prevalent among Thai adults with psoriasis, more pronounced with facial involvement, prior side-effect experience, and quality-of-life impairment. Individualized counseling is recommended to promote safe TCS use.
OBJECTIVES: To quantify TCS phobia using the TOPICOP scale in Thai adults with psoriasis and identify associated factors.
METHODS: A cross-sectional survey at Siriraj Hospital enrolled 150 adults with psoriasis and TCS experience, who completed the validated Thai TOPICOP scale.
RESULTS: Of 150 participants, 81 (54.0%) were female, median age 52 years (IQR 35.0-62.3). Mean TOPICOP score was 17.1 ± 5.3/36 (47.5% ± 14.7%). Forty percent reported explicit fear of TCS. Dermatologist-confirmed side effects, most commonly skin atrophy, were present in 50.0% and associated with higher TOPICOP scores (18.1 ± 4.3 vs. 16.0 ± 6.0; p = 0.016). Facial involvement was also associated with higher scores (18.1 ± 5.0 vs. 16.3 ± 5.4; p = 0.032). TOPICOP scores correlated positively with DLQI (r = 0.175; p = 0.030) and educational level (r = 0.240; p = 0.003).
CONCLUSIONS: TCS phobia is prevalent among Thai adults with psoriasis, more pronounced with facial involvement, prior side-effect experience, and quality-of-life impairment. Individualized counseling is recommended to promote safe TCS use.